Navigation Links
Immunomedics Reports Initial Clinical Results With Hpam4 For,Pancreatic Cancer Therapy

nal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancer, but not pancreatitis, normal pancreas or most other normal tissues. Preclinical studies with PAM4 labeled with the radioisotope, Yttrium-90, demonstrated favorable tumor responses, which could be further improved when given in combination with gemcitabine.

About Pancreatic Cancer

According to the National Cancer Institute, pancreatic cancer is the fourth leading cause of cancer death in the United States. In 2007, an estimated 37,000 Americans will be diagnosed with the disease, and about 33,000 patients will die from it. For patients with advanced cancers, the overall 5-year survival rate of all stages is less than 1%. For those patients with small and localized disease that can be completely resected surgically, 5-year survival rates improve to 18% to 24%. Currently, the standard therapy for pancreatic cancer is gemcitabine, alone or in combination with other chemotherapeutics.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We have licensed our lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. We have retained the rights for epratuzumab in oncology indications for which UCB has been granted a buy-in option. UCB has development, manufacture and commercialization rights, and is responsible for a
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/30/2014)... 30, 2014   Unique Pizza and Subs ... Pink: UPZS), a Delaware Corporation, is pleased to ... Larasan Pharmaceutical Corporation ("Larasan"), a nature-based pharmaceutical company that ... agreement, US-based Larasan will work with Unique to ... through Larasan,s vast distribution network throughout ...
(Date:7/30/2014)... and KISSING, Germany , July ... of a single use and computer-assisted ("robotic") colonoscopy system, ... , a worldwide recognized medical device executive, as a ... Mr. Shamir is a highly respected global visionary in ... he served as President and Chief Executive Officer at ...
(Date:7/30/2014)... and PARIS , July ... REGN ) and Sanofi (EURONEXT: SAN and NYSE: ... 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia ... reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at ... is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase ...
Breaking Medicine Technology:Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... 2011 Thoratec Corporation (NASDAQ: THOR ... support therapies to save, support and restore failing ... WiTricity Corporation relating to WiTricity,s proprietary wireless resonant ... of mechanical circulatory support. Through a ...
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today ... 2011, and reviewed recent developments. "In collaboration ... support the submission of our response to the FDA,s complete ... Lief, Arena,s President and Chief Executive Officer. "We are also ...
Cached Medicine Technology:Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology 2Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology 3Thoratec Announces Development Agreement With WiTricity for Proprietary Energy Transfer Technology 4Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments 8
(Date:7/30/2014)... revitalized and expanded through a U.S.-funded effort that ... access and providing cutting-edge skills labs and other ... by participants of the $130 million Medical Education ... progress being made at the African institutions. Their ... by the journal Academic Medicine . Begun ...
(Date:7/30/2014)... Alan Mozes HealthDay Reporter ... who want to help their preschooler shed excess pounds may ... Youngsters whose parents joined them in a supervised behavioral ... enrolled in a traditional child-only program (an average difference of ... benefited, losing almost 15 pounds over two years, according to ...
(Date:7/30/2014)... July 30, 2014 The family of ... has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) ... Bernstein Liebhard LLP reports. According to the complaint, which ... of Vermont on July 25th, the decedent had been ... an irreversible brain bleed that ultimately led to his ...
(Date:7/30/2014)... 2014) The phrase "we caught it early" is possibly ... midst of a cancer diagnosis. Combating cancer in its ... certain part of the body, gives patients the best ... colon, prostate and other forms of cancer are touted ... providers recommend cancer screenings as a precautionary measure, especially ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased ... Chack will serve as chair. The board was voted ... Learning Conference in Houston, Texas July 10-12. , ... of us. From the rollout of the first EDNF ... Baltimore Medical Center to our September physicians conference to ...
Breaking Medicine News(10 mins):Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2
... in China is smaller than that of many other countries, ... diabetics// of age between 20 and 79 in 2003. ... in China, while diabetics are mostly aged between 60 to ... Department in Beijing University People's Hospital. ,"Although no ...
... the Mecca of Fashion, Paris, have uncovered a mechanism ... natural chemical called opiorphin//, a natural pain alleviator, far ... their experiments, rodents were found to experience pain relief ... with the usual dosage of morphine. The finding which ...
... with incriminating evidence that warns non-vegetarians who binge on red ... out that eating more than one and a half servings ... breast cancer and another study that vitamin supplements seem ... diseases except for vitamin C which seems to show some ...
... fatty acid known as docosahexaenoic acid (DHA) in their ... dementia and Alzheimer’s disease, according to a study. ... been found to increase the risk of dementia and ... of cases of dementia in the elderly, according to ...
... Shelnutt and Yujiang Song from Sandia National Laboratories have ... attaches //to a cell which involves a new process that ... Security Administration laboratory. ,An upcoming issue of the German ... Angewandte Chemie Int. Ed which has currently published the same ...
... be just a matter of eating a salad a day. ... Americans will welcome a new study that could keep them ... study, conducted by the UCLA School of Public Health and ... revealed eating salads with salad dressing and raw vegetables is ...
Cached Medicine News:Health News:Red alert to women against red meat consumption 2Health News:Higher Level of Certain Fatty Acid Associated with Lower Dementia Risk 2Health News:Novel methods to view how a drug attaches to a cell 2Health News:A Salad a Day Keeps the Doctor Away This Winter 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: